Hereditary Cancer SyndromesNCT07901543
Feasibility Study of a Chatbot AI-Driven Preliminary Screening System for Hereditary Cancer Syndromes
An observational study of Hereditary Cancer Syndromes, run by National Cancer Centre, Singapore at 1 site in Singapore.
Trial summary
This study aims to assess the feasibility of implementing an AI-based hereditary cancer preliminary screening system that has already been developed. This validation cohort will consist of healthy individuals and cancer patients, including those already suspected to be at risk of hereditary conditions. Read more about this study
- Who is it for?
- Ages 21 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Hereditary Cancer Syndromes
- What is being tested?
- Hereditary cancer preliminary screening chatbot
- How many people
- 200 participants
- Where
- 1 siteSingapore
- Study dates
- 21 Jul 2026to 21 Jul 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Both patients and the healthy population in Singapore.
Who may be able to join
- Singapore citizen or permanent resident
- Individuals from the general public or patients at NCCS
- Adults (aged 21 or older) who are capable of giving informed consent
Who cannot join
- Under the age of 21 years old
- Incapable of giving informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Caitlin Nicole Samy Victoria contact
Singapore1 site, 1 recruiting
- Recruiting
National Cancer Center Singapore
Singapore, 168583
Dr Joanne Ngeow, +65 6306 5904, joanne.ngeow.y.y@singhealth.com.sg
About this study
This study aims to assess the feasibility of implementing an AI-based hereditary cancer preliminary screening system that has already been developed. This validation cohort will consist of healthy individuals and cancer patients, including those already suspected to be at risk of hereditary conditions.
Read the detailed description
The preliminary screening of genetic cancer risk is not currently practical in cancer patients and healthy populations. It is time-consuming, inconsistent in quality, and inefficient when conducted manually. Given these limitations, artificial intelligence (AI) has gained attention as a potential tool for genetic risk assessment. Among AI technologies, Chatbots have been explored for their ability to facilitate patient communication and provide preliminary risk assessment, particularly in the context of hereditary cancers.
The investigators recently developed a new AI-based hereditary cancer preliminary screening system to identify high-risk people with genetic backgrounds. This system can assess the risk for hereditary breast and ovarian cancer (HBOC), lynch syndrome, and Li-Fraumeni syndrome, the major hereditary diseases. By conducting a feasibility study in Singapore, the investigators aim to assess the applicability of this system. The study will be conducted at the National Cancer Centre Singapore (NCCS), targeting both patients and members of the general Singaporean population. This system is expected to improve efficiency, ensure consistent quality, and expand access to genetic healthcare services across different populations and regions by automating preliminary screening. The system will be utilized to evaluate its operation completion rate and medical accuracy. After using the system, a survey will be conducted among the study participants to assess the system's usability.
- Conditions
- Hereditary Cancer Syndromes
- Being tested
- Hereditary cancer preliminary screening chatbot
- Keywords
- Hereditary cancer, Familial cancer, Genetic counselling, Artificial intelligence, Augmented intelligence, Preliminary screening, Chatbot, Screening, Feasibility, IBM Watson, Family history, Medical history, Conversational agent
- Medical subject headings
- Neoplastic Syndromes, Hereditary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hereditary cancer preliminary screening chatbotOther
Patients will answer questions through the chatbot interface, which evaluates whether they meet HBOC, lynch syndrome, and Li-Fraumeni syndrome testing criteria based on their personal and family medical history. After using the system, a survey will be conducted among the study participants to assess the system's usability.
| Study group | Role | What they receive |
|---|---|---|
| Participant interaction with an AI-based hereditary cancer preliminary screening system | Group/Cohort Description: the system will be utilized to evaluate its operation completion rate and medical accuracy. Receives: Other: Hereditary cancer preliminary screening chatbot |
What is being measured
The primary outcome is the main question the study is designed to answer.
Completion rate
Completion rate of the hereditary cancer preliminary screening system using the Chatbot
Measured: Immediately after completion of chatbot assessment.
Secondary outcomes (3)
Chatbot assessment completion time
Time required to operate the hereditary cancer preliminary screening system using the Chatbot.
Measured: Immediately after completion of chatbot assessment.
Consistency rate
Consistency rate between the medical and family history related to hereditary cancers collected by the Chatbot and those provided by participants.
Measured: Immediately after completion of chatbot assessment.
System Usability Scale score and participant feedback
Quantitative and qualitative data from multiple-choice and open-ended questionnaire surveys using the System Usability Scale.
Measured: Immediately after completion of chatbot assessment and questionnaire, up to 1 day.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2026
- Study start21 Jul 2026
- Primary completion21 Jul 2027 (estimated)
- Study completion21 Jul 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hereditary Cancer SyndromesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Cancer Centre, Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- Kanagawa University of Human Services
- Responsible party
- Sponsor
- Investigators
- Dr Joanne Ngeow, MBBS, MRCP, MPH, PhD, Principal investigator, National Cancer Centre, Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07901543
- Sponsor's protocol ID
- 2025-1116
- Status last verified
- Oct 2026
- First submitted
- 22 Oct 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility Study of a Chatbot AI-Driven Preliminary Screening System for Hereditary Cancer Syndromes
- ClinicalTrials.gov ID
- NCT07901543
- Acronym / sponsor ID
- 2025-1116
- Conditions
- Hereditary Cancer Syndromes
- Keywords
- Hereditary cancer, Familial cancer, Genetic counselling, Artificial intelligence, Augmented intelligence, Preliminary screening, Chatbot, Screening
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- National Cancer Centre, SingaporeUniversity, hospital or other
- Collaborators
- Kanagawa University of Human Services
- Study start
- 21 Jul 2026 (actual)
- Primary completion
- 21 Jul 2027 (estimated)
- Study completion
- 21 Jul 2029 (estimated)
- First posted
- 28 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to assess the feasibility of implementing an AI-based hereditary cancer preliminary screening system that has already been developed. This validation cohort will consist of healthy individuals and cancer patients, including those already suspected to be at risk of hereditary conditions.
Detailed description
The preliminary screening of genetic cancer risk is not currently practical in cancer patients and healthy populations. It is time-consuming, inconsistent in quality, and inefficient when conducted manually. Given these limitations, artificial intelligence (AI) has gained attention as a potential tool for genetic risk assessment. Among AI technologies, Chatbots have been explored for their ability to facilitate patient communication and provide preliminary risk assessment, particularly in the context of hereditary cancers.
The investigators recently developed a new AI-based hereditary cancer preliminary screening system to identify high-risk people with genetic backgrounds. This system can assess the risk for hereditary breast and ovarian cancer (HBOC), lynch syndrome, and Li-Fraumeni syndrome, the major hereditary diseases. By conducting a feasibility study in Singapore, the investigators aim to assess the applicability of this system. The study will be conducted at the National Cancer Centre Singapore (NCCS), targeting both patients and members of the general Singaporean population. This system is expected to improve efficiency, ensure consistent quality, and expand access to genetic healthcare services across different populations and regions by automating preliminary screening. The system will be utilized to evaluate its operation completion rate and medical accuracy. After using the system, a survey will be conducted among the study participants to assess the system's usability.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participant interaction with an AI-based hereditary cancer preliminary screening system | – | Other: Hereditary cancer preliminary screening chatbotGroup/Cohort Description: the system will be utilized to evaluate its operation completion rate and medical accuracy. |
Who may qualify
- Ages
- 21 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Both patients and the healthy population in Singapore.
Key inclusion criteria (3 listed)
- Singapore citizen or permanent resident
- Individuals from the general public or patients at NCCS
- Adults (aged 21 or older) who are capable of giving informed consent
Key exclusion criteria (2 listed)
- Under the age of 21 years old
- Incapable of giving informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hereditary cancer preliminary screening chatbotPatients will answer questions through the chatbot interface, which evaluates whether they meet HBOC, lynch syndrome, and Li-Fraumeni syndrome testing criteria based on their personal and family medical history. After using the system, a survey will be conducted among the study participants to assess the system's usability. | Other | Participant interaction with an AI-based hereditary cancer preliminary screening system |
Primary outcome
Completion rate
Time frame: Immediately after completion of chatbot assessment.
Completion rate of the hereditary cancer preliminary screening system using the Chatbot
3 secondary outcomes
Chatbot assessment completion time
Time frame: Immediately after completion of chatbot assessment.
Consistency rate
Time frame: Immediately after completion of chatbot assessment.
System Usability Scale score and participant feedback
Time frame: Immediately after completion of chatbot assessment and questionnaire, up to 1 day.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Hereditary Cancer Syndromes
Active, not recruitingPhase 3
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Colon Adenocarcinoma, DNA Repair Disorder
Not yet recruitingPhase 2
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor
MPNST (Malignant Peripheral Nerve Sheath Tumor)
Enrolling by invitation
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
Adenocarcinoma, Prostate Neoplasms
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
RecruitingPhase 1
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
NF1 Mutation, Neurofibroma Plexiform
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Caitlin Nicole Samy Victoria contact
Dr Joanne Ngeow, MBBS, MRCP, MPH, PhD principal investigator
National Cancer Centre, Singapore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hereditary Cancer Syndromes, run by National Cancer Centre, Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dr Joanne Ngeow, MBBS, MRCP, MPH, PhD (+65 6306 5904, joanne.ngeow.y.y@singhealth.com.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Completion rate (time frame: Immediately after completion of chatbot assessment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.